Leptin for Obesity: Previous Failures, Promising Future
Avraham Marcucci1, Jamie Mullally2, William H Frishman1
1From the Department of Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.
Cardiology in Review
|June 19, 2025
Summary
Leptin, a key obesity research hormone, shows potential in new combination therapies. Targeting hypothalamic neurons with leptin and GLP-1 agonists may reduce food intake and body weight.
Area of Science:
- Endocrinology
- Metabolic Research
- Neuroscience
Background:
- Leptin, discovered in 1950, is vital for regulating energy balance and obesity physiology.
- Recombinant leptin effectively reduced weight in deficient models but faced resistance in diet-induced obesity.
- Previous combination therapies with amylin showed promise but encountered antibody development issues.
Purpose of the Study:
- To explore novel therapeutic strategies for obesity management.
- To investigate the efficacy of combining leptin with other agents.
- To identify new targets for weight reduction therapies.
Main Methods:
- Review of historical and recent obesity research findings.
- Analysis of leptin's role in energy balance and weight regulation.
- Examination of combination therapy approaches, including leptin with amylin and GLP-1 receptor agonists.
Main Results:
- Leptin is crucial for energy balance, though leptin resistance limits its use in diet-induced obesity.
- Combination therapies, such as leptin with amylin, have shown enhanced weight loss.
- Emerging research indicates combining leptin with GLP-1 receptor agonists may reduce food intake and body weight.
Conclusions:
- Leptin remains a critical factor in obesity research and treatment.
- Combination therapies offer a promising avenue for overcoming leptin resistance.
- Targeting specific hypothalamic neurons with leptin and GLP-1 agonists presents a potential strategy for weight management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
01:24Obesity
627
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
627
01:30Regulation of Food Intake
533
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
533
01:28Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
01:24Overview of Lipid Metabolism
2.6K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.6K
01:23Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271